Navigation Links
Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry

In the agreement between the two Toronto-area companies, Microbix will maintain sales and marketing functions while Therapure will manage manufacturing, distribution and product development

Toronto, Ontario (PRWEB) January 13, 2010 -- Microbix Biosystems Inc. (MBX:TSX) a biotechnology company focused on virology and biological technologies, and Therapure Biopharma Inc., an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins, announced today the signing of a partnership agreement to manufacture and market water-based products to the pharmaceutical, biotechnology and other industries.

The partnership will significantly expand the portfolio of products Microbix will offer its customers and increase capacity by leveraging Therapure’s state-of-the-art, commercial scale manufacturing facility. Under terms of the agreement, Microbix will maintain the sales and marketing functions for the water-based program, while Therapure will manage manufacturing and product development operations. The products will remain under the Microbix brand. Further financial details of the transaction were not made public.

Microbix, whose water-based product sales have nearly doubled each year since 2006, will benefit from the agreement due to Therapure’s large manufacturing capacity, its R&D expertise as well as its testing, filling, packaging and shipping services. Therapure will gain by tapping into Microbix’ established market position as a leading water-based products supplier to the North American pharmaceutical industry.

Microbix CEO William J. Gastle said, “Therapure’s capabilities will enable Microbix to expand our product line and market share of the growing water-based business in North America. Our partnership will enable us to provide a complete portfolio of water-based products which will drive sales higher while increasing customer satisfaction.”

“Water-based products are an important part of Microbix’ core business, which has been growing by more than 20% for the past six years. Our core business also represents significant contributions to our total revenue,” Gastle added.

Thomas Wellner, President and CEO of Therapure said, “Therapure Biopharma is excited to partner with another Canadian-based biotechnology company. This opportunity enables Therapure to leverage our large water and buffer manufacturing capacity and our Health Canada licensed aseptic filling capabilities.”

The immediate result of the Microbix-Therapure agreement will be the launch of Microbix 22™, a new 22% alcohol and water-for-injection (WFI) pre-mixed used for chromatography column storage. Mixing concentrated alcohol with water can be dangerous and many customers would rather purchase the product premixed and avoid the risks. Additionally, the partnership will be able to manufacture custom buffers and media to recipes provided by customers.

About Microbix:
Microbix specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Toronto.

About Therapure Biopharma:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its’ clients. Therapure’s Health Canada licensed 130,000 sq.ft. facility, includes manufacturing, research and quality control laboratories and a cGMP warehouse, is built to U.S. FDA, EMEA, MHRA and Health Canada standards for the aseptic handling and purification of proteins.

This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with failure to , develop and commercialize new products on a timely basis, non-adoption of products by new customers, resistance to business model for commercialization and implementation; risks associated with commercializing new products; and risks associated with outsourcing production including control over costs, quality, quantity and timeliness of delivery of products. These forward-looking statements represent the Companies’ judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. SEDAR: 00004220E


Please visit:
Or contact:
William J. Gastle, CEO, (416) 234-1624 x 230;
James Long, CFO, (416) 234-1624 x 265

Please visit:
Or contact:
Thomas Wellner, President and CEO, (905) 286-6204
Raj Puri, Director Business Development, (905) 286-6232
ceo (at) therapurebio (dot) com


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
2. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
3. Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
4. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
5. Seven More Biopharmaceutical Research Companies Join PhRMA
6. BioProcess International Launches a New and Improved Website for Biopharmaceutical Managers and Scientists
7. Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
8. Leading Biopharmaceutical Company Selects Stimar for Code of Conduct Regulation Training
9. OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners
10. Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top
11. aTyr Pharma to Present at Japan Biopharma Partnering Conference
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... for the care management and population health arenas, is pleased to announce that ... cost containment services, has successfully implemented the ACUITY Complete Care™ Management to back ...
(Date:12/1/2015)... ... 2015 , ... With FCPX Overlay: Grit , users can apply a ... possibilities are truly endless, all with a click of a mouse. Each user has ... flip, depth of field and more, all within Final Cut Pro X. , With ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani ... Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled ... Contact Center solutions targeted to the high-end enterprise contact center marketplace. , Ed ...
(Date:11/30/2015)... ... December 01, 2015 , ... The Turks & Caicos Islands has enjoyed being ... news sites highlighting Caribbean destinations, has published five reasons to visit the Turks & ... shivers under chilly grey skies or worse, it's typically a balmy 80 degrees in ...
(Date:11/30/2015)... ... November 30, 2015 , ... 1Heart Caregiver Services’ ... the Federation of Philippine American Chambers of Commerce held from November 6-8, 2015 ... 1Heart Caregiver Services, as an active delegate from the Philippine American Chamber of ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , November 30, 2015 ... --> adds a 2015 ... 2010 - 2015 with comprehensive analysis ... range of deal types, such as ... alliances. . ...
(Date:11/30/2015)... , Nov. 30, 2015  Kevin Smith has ... Healthcare, a global pioneer in wireless monitoring of ... Boston, MA , Mr. Smith will be ... global commercial strategy.  He will also directly oversee ... build clinical evidence for SensiumVitals, the first early ...
(Date:11/30/2015)... , Nov. 30, 2015  The ... norm in U.S. medical imaging is on ... popular accountable care payer-provider contracts are set ... in their wake, alter provider-vendor relationships. The ... will push forward new purchasing frameworks in ...
Breaking Medicine Technology: